As of 30 June, there have been 100 preliminary reports of Guillain-Barré syndrome in the US out of 12.8 million Johnson and Johnson vaccine doses given.
Business & Regulation
Analysis of jobs, deals, stock prices and financial filings and news sentiments now show pharma to be a relative winner when it comes to Covid-19 recovery.
The US Food and Drug Administration's (FDA) recent approval of Biogen's Aduhelm could signify a new era for the treatment of Alzheimer's disease.
2021 is seen as a year of catch-up for the Internet of Things. But IoT cyber security issues which dogged the tech in the 2010s continue to do so, Giacomo Lee explains.